U.S. markets close in 3 hours 48 minutes
  • S&P 500

    3,668.35
    -76.17 (-2.03%)
     
  • Dow 30

    29,491.03
    -435.91 (-1.46%)
     
  • Nasdaq

    10,746.86
    -326.45 (-2.95%)
     
  • Russell 2000

    1,712.72
    -39.79 (-2.27%)
     
  • Crude Oil

    92.44
    +3.99 (+4.51%)
     
  • Gold

    1,711.50
    -9.30 (-0.54%)
     
  • Silver

    20.28
    -0.38 (-1.84%)
     
  • EUR/USD

    0.9787
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    3.8610
    +0.0350 (+0.91%)
     
  • GBP/USD

    1.1123
    -0.0045 (-0.41%)
     
  • USD/JPY

    145.1660
    +0.0980 (+0.07%)
     
  • BTC-USD

    19,577.46
    -456.78 (-2.28%)
     
  • CMC Crypto 200

    446.39
    -8.64 (-1.90%)
     
  • FTSE 100

    6,991.09
    -6.18 (-0.09%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

Is Most-Watched Stock Teladoc Health, Inc. (TDOC) Worth Betting on Now?

·5 min read

Teladoc (TDOC) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this telehealth services provider have returned +11.5% over the past month versus the Zacks S&P 500 composite's -6.6% change. The Zacks Medical Services industry, to which Teladoc belongs, has lost 8.9% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate Revisions

Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Teladoc is expected to post a loss of $0.71 per share, indicating a change of +17.4% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of -$43.18 for the current fiscal year indicates a year-over-year change of -3,146.6%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of -$1.64 indicates a change of +96.2% from what Teladoc is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Teladoc is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

12-month consensus EPS estimate for TDOC _12MonthEPSChartUrl
12-month consensus EPS estimate for TDOC _12MonthEPSChartUrl

Projected Revenue Growth

Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Teladoc, the consensus sales estimate of $586.79 million for the current quarter points to a year-over-year change of +16.6%. The $2.42 billion and $2.9 billion estimates for the current and next fiscal years indicate changes of +19.1% and +20%, respectively.

Last Reported Results and Surprise History

Teladoc reported revenues of $565.35 million in the last reported quarter, representing a year-over-year change of +24.6%. EPS of -$0.47 for the same period compares with $0.13 a year ago.

Compared to the Zacks Consensus Estimate of $568.91 million, the reported revenues represent a surprise of -0.63%. The EPS surprise was +14.55%.

Over the last four quarters, Teladoc surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

Valuation

No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Teladoc is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom Line

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Teladoc. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.